Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

Abstract

Objective:

To review the pharmacology, efficacy, and safety of revumenib (Revuforj) for relapsed or refractory (r/r) acute leukemia with a lysine methyltransferase 2A (KMT2A) gene rearrangement or translocation (KMT2Ar).

Data Sources:

A literature search was conducted using PubMed/MEDLINE, applicable published abstracts, and ongoing studies from ClinicalTrials.gov between January 1, 1981, and April 23, 2025. Keywords included Revuforj, revumenib, SNDX-5613, KMT2A, MLL1, and menin.

Study Selection and Data Extraction:

All English-language studies involving revumenib for r/r acute leukemia with a KMT2Ar were included.

Data Synthesis:

Revumenib, a protein-protein inhibitor that interrupts the interaction between the KMT2A protein and the scaffold protein menin, was granted approval by the Food and Drug Administration (FDA) for r/r acute leukemia with KMT2Ar based on a phase 2 clinical trial in adult and pediatric patients (n = 57), which reported a complete remission or complete remission with partial hematologic recovery of 22.8%. Common grade 3/4 adverse reactions reported for revumenib include infectious (febrile neutropenia 33%; infection 29%; bacterial infection 20%) and hematologic events (differentiation syndrome 13%; hemorrhage 9%; thrombosis 5%). Grade 3/4 QT prolongation, the primary dose-limiting adverse effect, was present in 12% of patients. Differentiation syndrome, related to revumenib’s antileukemic effect, was observed in 29% of patients (grade 3/4: 13%; grade 5: <1%). We also include long-term follow-up for a total of 104 and 135 patients for efficacy and safety results, respectively.

Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:

In the high-risk disease of r/r acute leukemia with KMT2Ar, given limited treatment options, revumenib appears to be a viable, novel treatment option demonstrating clinical efficacy and a manageable adverse effect profile that can be utilized as a bridge to stem cell transplant. Existing therapy options in this setting may include additional traditional chemotherapy, chimeric antigen receptor T-cell therapy (CAR-T), antibody-drug conjugates (eg, gemtuzumab, inotuzumab), bispecific T-cell engager (BiTE) therapies (eg, blinatumomab), DNA methyltransferase inhibitors (eg, azacitidine, decitabine), histone deacetylase inhibitors (eg, vorinostat, panobinostat), and BCL-2 inhibitors (venetoclax).

Conclusions:

Revumenib is an innovative targeted treatment with promising activity in r/r acute leukemia with KMT2Ar.

Keywords

ALL AML KMT2Ar leukemia SNDX-5613-0700 NCT04065399 AUGMENT-101 revuforj

Get full access to this article

View all access options for this article.

References

Mertens

Yong

Dietz

, et al Conditional survival in pediatric malignancies: analysis of data from the childhood cancer survivor study and the surveillance, epidemiology, and end results program. Cancer. 2015;121:1108-1117. doi:10.1002/cncr.29170

Siegel

Giaquinto

Jemal

Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12-49. doi:10.3322/caac.21820

Pollard

Guest

Alonzo

, et al Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric. J Clin Oncol. 2021;39:3149-3160. doi:10.1200/JCO.20.03048

Rau

Gupta

Kairalla

, et al Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk pediatric B-acute lymphoblastic leukemia: results from the randomized children’s oncology group study AALL1731. Blood. 2024;144(suppl 1):1. doi:10.1182/blood-2024-207450

Coustan-Smith

Sancho

Hancock

, et al Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.

Johnston

Alonzo

Gerbing

, et al Central nervous system disease in pediatric acute myeloid leukemia: a report from the children’s oncology group. Pediatr Blood Cancer. 2017;64(12):e26612. doi:10.1002/pbc.26612

Oskarsson

Söderhäll

Arvidson

, et al Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101(1):68-76. doi:10.3324/haematol.2015.131680

White

Kaspers

Abrahamsson

, et al Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: a retrospective study within the NOPHO-DB SHIP consortium. Br J Haematol. 2022;197(6):755-765. doi:10.1111/bjh.18039

Issa

Zarka

Sasaki

, et al Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162. doi:10.1038/s41408-021-00557-6

10.

Pui

Chessells

Camitta

, et al Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003;17(4):700-706. doi:10.1038/sj.leu.2402883

11.

Issa

Aldoss

Thirman

, et al Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75-84. doi:10.1200/JCO.24.00826

12.

Kwon

Thuring

Querolle

, et al Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024;144:1206-1220. doi:10.1182/blood.2023022480

13.

US Food and Drug Administration. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. Accessed April 15, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation

14.

Micheel

Sweeney

LeNoue-Newton

, et al American association for cancer research project genomics evidence neoplasia information exchange: from inception to first data release and beyond-lessons learned and member institutions’ perspectives. JCO Clin Cancer Inform. 2018;2:1-14. doi:10.1200/CCI.17.00083

15.

Cerami

Gao

Dogrusoz

, et al The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404. doi:10.1158/2159-8290.CD-12-0095

16.

Gao

Aksoy

Dogrusoz

, et al Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi:10.1126/scisignal.2004088

17.

Seligson

Kautto

Passen

, et al BRCA1/2 functional loss defines a targetable subset in leiomyosarcoma. Oncologist. 2019;24(7):973-979. doi:10.1634/theoncologist.2018-0448

18.

Kundra

Zhang

Sheridan

, et al OncoTree: a cancer classification system for precision oncology. JCO Clin Cancer Inform. 2021;5:221-230. doi:10.1200/CCI.20.00108

19.

Bill

Mrózek

Kohlschmidt

, et al Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci U S A. 2020;117:26340-26346. doi:10.1073/pnas.2014732117

20.

Baer

Stewart

Lawrence

, et al Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998;12(3):317-325. doi:10.1038/sj.leu.2400933

21.

Ley

Miller

Ding

, et al Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-2074. doi:10.1056/NEJMoa1301689

22.

Pui

Gaynon

Boyett

, et al Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359: 1909–1915. doi:10.1016/S0140-6736(02)08782-2

23.

Balgobind

Raimondi

Harbott

, et al Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489-2496. doi:10.1182/blood-2009-04-215152

24.

Szczepański

Harrison

van Dongen

JJ.

Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol. 2010;11(9):880-889. doi:10.1016/S1470-2045(09)70369-9

25.

Meyer

Larghero

Almeida Lopes

, et al The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37(5):988-1005. doi:10.1038/s41375-023-01877-1

26.

Ray

Clegg

Grembecka

Cierpicki

Drug-resistant menin variants retain high binding affinity and interactions with MLL1. J Biol Chem. 2024;300(10):107777. doi:10.1016/j.jbc.2024.107777

27.

Krivtsov

Evans

Gadrey

, et al A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660-73e11. doi:10.1016/j.ccell.2019.11.001

28.

Issa

Aldoss

DiPersio

, et al The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920-924. doi:10.1038/s41586-023-05812-3

29.

Perner

Stein

Wenge

, et al MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023; 615(7954):913-919. doi:10.1038/s41586-023-05755-9

30.

Attwa

Abdelhameed

Kadi

AA.

An ultra-fast validated green UPLC-MS/MS approach for assessing revumenib in human liver microsomes: in vitro absorption, distribution, metabolism, and excretion and metabolic stability evaluation. Medicina (Kaunas). 2024;60(12):1914. doi:10.3390/medicina60121914

31.

Syndax Pharmaceuticals Inc. Revuforj (Revumenib) [package insert]. Syndax Pharmaceuticals, Inc.; 2024.

32.

Chapron

Barter

Jones

, et al Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias [abstract]. Paper presented at the American Conference on Pharmacomentrics Annual Conference; April 2024; San Diego, CA.

33.

McGeehan

A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias [abstract]. Paper presented at the American Association for Cancer Research Annual Meeting; June 2020; Virtual Meeting.

34.

Issa

Cuglievan

Stein

, et al Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience [abstract]. Blood. 2022;140(suppl 1):914-916. doi:10.1182/blood-2022-164600

35.

Cuglievan

Dickens

Shenoy

, et al Menin inhibition in pediatric KMT2Ar leukemia: phase 1 and expanded access experience with revumenib [abstract]. Paper presented at the Pediatric Blood and Cancer 2023; ASPHO Annual Meeting. May 2023; Fort Worth, TX.

36.

Zucenka

Issa

Arellano

, et al Revumenib maintenance therapy following revumenib-induced remission and transplant [abstract]. Blood. 2023;142(suppl 1):4950.

37.

Tauveron-Jalenques

Sarr

Guièze

, et al Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia. Ann Hematol. 2024;103(12):5985-5988. doi:10.1007/s00277-024-06127-7

38.

Correction to: abstracts of the 100th Annual Meeting June 6-9, 2024 Olympic Valley, California [abstract] [published online ahead of print September 16, 2024]. J Neuropathol Exp Neurol. doi:10.1093/jnen/nlae102

39.

Syndax Inc. Syndax announces FDA approval of Revuforj^® (Revumenib), the first and only menin inhibitor to treat adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation. Accessed April 15, 2025. https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-approval-revuforjr-revumenib-first-and-only

40.

Syndax Inc. Wholesale acquisition cost information for Colorado prescribers. Accessed April 15, 2025. https://cms.syndax.com/wp-content/uploads/2024/11/co_wac_disclosure_REVUFORJ-1.pdf

41.

Syndax Inc. Connecticut HB 6669—REVUFORJ® (Revumenib). Accessed April 15, 2025: https://cms.syndax.com/wp-content/uploads/2024/11/CT-Disclosure-REVUFORJ-1.pdf

42.

Issa

Ravandi

DiNardo

Jabbour

Kantarjian

Andreeff

Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482-2495. doi:10.1038/s41375-021-01309-y

43.

Myers

Taraseviciute

Steinberg

, et al Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:932-944. doi:10.1200/JCO.21.01405

44.

Campbell

Haladyna

Drubin

, et al Mechanisms of pinometostat (EPZ-5676) treatment-emergent resistance in. Mol Cancer Ther. 2017;16(8):1669-1679. doi:10.1158/1535-7163.MCT-16-0693

45.

Konopleva

Pollyea

Potluri

, et al Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106-1117. doi:10.1158/2159-8290.CD-16-0313

46.

Platzbecker

Middeke

Sockel

, et al Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12): 1668-1679. doi:10.1016/S1470-2045(18)30580-1

47.

Bataller

Abuasab

McCall

, et al Myeloid lineage switch in KMT2A- rearranged acute lymphoblastic leukemia treated with lymphoid lineage directed therapies. Haematologica. 2024;109:293-297. doi:10.3324/haematol.2023.283705

48.

US Food and Drug Administration. NDA 218944 approval letter. Accessed April 15, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218944Orig1s000ltr.pdf

49.

Candoni

Coppola

A 2024 update on menin inhibitors. a new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep. 2024;16:244-254. doi:10.3390/hematolrep16020024

50.

National Library of Medicine. Accessed April 15, 2025. https://clinicaltrials.gov